Sera Prognostics Inc - Ordinary Shares Class A Aktie News

Sera Prognostics' PreTRM test shows strong clinical utility in reducing neonatal morbidity and NICU admissions, outperforming standard cervical length screening. The company is well-capitalized with $114 million in cash, sufficient to fund commercialization efforts into 2028, despite current losses. Key growth drivers include commercial reimbursement, Medicaid coverage, and inclusion in clinica...

SALT LAKE CITY , May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conferen...

SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, ...

Sera Prognostics Inc (NASDAQ:SERA ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Zhenya Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen. Operator Good afternoon and welcome to the Sera Prognostics Conference Call to review First Quarter Fiscal Year 2025 Results.

Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY , May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Comme...

SALT LAKE CITY , May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment ...

SALT LAKE CITY , April 24, 2025 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company...

Sera Prognostics Inc (NASDAQ:SERA ) Q4 2024 Earnings Conference Call March 19, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Evguenia Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen Margarate Boeye - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Fourth ...